title: Apoptotic effect of cisplatin and cordycepin on OC3 human oral cancer cells.
abstract: OBJECTIVE
  To evaluate apoptotic effects of cisplatin and cordycepin as single agent or in combination with cytotoxicity in oral cancer cells.
  
  
  METHODS
  The influences of cisplatin (2.5 μg/mL) and/or cordycepin treatment (10 or 100 μmol/L) to human OC3 oral cancer cell line were investigated by morphological observation for cell death appearance, methylthiazoletetrazolium (MTT) assay for cell viability, flow cytometry assay for cell apoptosis, and Western blotting for apoptotic protein expressions.
  
  
  RESULTS
  Data demonstrated that co-administration of cisplatin (2.5 μg/mL) and cordycepin (10 or 100 μmol/L) resulted in the enhancement of OC3 cell apoptosis compared to cisplatin or cordycepin alone treatment (24 h), respectively (P <0.05). In flow cytometry assay, percentage of cells arrested at subG1 phase with co-treatment of cordycepin and cisplatin (30%) was significantly higher than cisplatin (5%) or cordycepin (12%) alone group (P <0.05), confirming a synergistically apoptotic effect of cordycepin and cisplatin. In cellular mechanism study, co-treatment of cordycepin and cisplatin induced more stress-activated protein kinase/Jun terminal kinase (JNK), the expressions of caspase-7, and the cleavage of poly ADP-ribose polymerase (PARP) as compared to cisplatin or cordycepin alone treatment (P <0.05).
  
  
  CONCLUSIONS
  Cisplatin and cordycepin possess synergistically apoptotic effect through the activation of JNK/caspase-7/PARP pathway in human OC3 oral cancer cell line.
authors.affiliation: Department of Anesthesia, Chi-Mei Medical Center, Liouying, Tainan, Taiwan, China.
authors.forename: Ying-hui
authors.initials: YH
authors.lastname: Chen
authors.forename: Lyh-Jyh
authors.initials: LJ
authors.lastname: Hao
authors.forename: Chih-peng
authors.initials: CP
authors.lastname: Hung
authors.forename: Jung-wei
authors.initials: JW
authors.lastname: Chen
authors.forename: Sew-fen
authors.initials: SF
authors.lastname: Leu
authors.forename: Bu-miin
authors.initials: BM
authors.lastname: Huang
mesh_terms: D017209:Apoptosis / Q000187:drug effects*; D053179:Caspase 7 / Q000378:metabolism; D002452:Cell Count; D045744:Cell Line, Tumor; D048430:Cell Shape / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002945:Cisplatin / Q000494:pharmacology*; D003839:Deoxyadenosines / Q000494:pharmacology*; D004357:Drug Synergism; D016193:G1 Phase / Q000187:drug effects; D006801:Humans; D048031:JNK Mitogen-Activated Protein Kinases / Q000378:metabolism; D009062:Mouth Neoplasms / Q000473:pathology*; D010766:Phosphorylation / Q000187:drug effects; D011065:Poly(ADP-ribose) Polymerases / Q000378:metabolism
chemical_list: D003839:Deoxyadenosines; D011065:Poly(ADP-ribose) Polymerases; D048031:JNK Mitogen-Activated Protein Kinases; D053179:Caspase 7; C058120:cordycepin; D002945:Cisplatin
references.citation: J Oral Pathol Med. 2004 Feb;33(2):79-86
references.pmid: 14720193
references.citation: Oncol Rep. 2004 Nov;12(5):955-65
references.pmid: 15492778
references.citation: Exp Cell Res. 2000 May 25;257(1):111-26
references.pmid: 10854059
references.citation: Int J Biochem Cell Biol. 2005 Jan;37(1):214-23
references.pmid: 15381163
references.citation: Anticancer Res. 2005 Nov-Dec;25(6C):4445-9
references.pmid: 16334124
references.citation: Cell. 2004 Jan 23;116(2 Suppl):S53-6, 1 p following S59
references.pmid: 15055582
references.citation: J Biol Chem. 1999 Aug 13;274(33):22932-40
references.pmid: 10438458
references.citation: Oral Oncol. 2001 Sep;37(6):477-92
references.pmid: 11435174
references.citation: Arch Biochem Biophys. 2009 Oct 15;490(2):103-9
references.pmid: 19733546
references.citation: Biol Chem. 2005 May;386(5):471-80
references.pmid: 15927891
references.citation: Anticancer Res. 2006 Jan-Feb;26(1A):43-7
references.pmid: 16475677
references.citation: J Immunol Methods. 1991 Jun 3;139(2):271-9
references.pmid: 1710634
references.citation: Curr Med Chem. 2009;16(4):394-416
references.pmid: 19199913
references.citation: J Biol Chem. 2010 Jan 22;285(4):2610-21
references.pmid: 19940154
references.citation: J Oral Pathol Med. 2002 Apr;31(4):213-9
references.pmid: 12076324
references.citation: Carcinogenesis. 2003 Aug;24(8):1361-7
references.pmid: 12819185
references.citation: Acta Otolaryngol. 2005 Jul;125(7):779-85
references.pmid: 16012042
references.citation: Life Sci. 2001 Nov 9;69(25-26):2957-64
references.pmid: 11758823
references.citation: J Biol Chem. 2002 Aug 16;277(33):29792-802
references.pmid: 12058028
references.citation: Cancer Chemother Pharmacol. 2007 Jun;60(1):103-11
references.pmid: 17031645
references.citation: J Urol. 2011 Mar;185(3):1102-11
references.pmid: 21255805
references.citation: Cancer Chemother Pharmacol. 1995;35(6):471-82
references.pmid: 7533669
references.citation: Gynecol Oncol. 2006 Aug;102(2):348-55
references.pmid: 16545436
references.citation: N Engl J Med. 2003 Nov 27;349(22):2091-8
references.pmid: 14645636
references.citation: Drug Resist Updat. 2004 Apr;7(2):97-110
references.pmid: 15158766
references.citation: Int J Cancer. 2009 Jun 1;124(11):2643-50
references.pmid: 19253368
references.citation: Anticancer Res. 2006 Mar-Apr;26(2B):1651-5
references.pmid: 16619587
references.citation: Laryngoscope. 2007 Aug;117(8):1381-8
references.pmid: 17607147
references.citation: J Biol Chem. 2004 Oct 22;279(43):44713-22
references.pmid: 15302867
references.citation: Addict Biol. 2002 Jan;7(1):77-83
references.pmid: 11900626
references.citation: Food Chem Toxicol. 2010 Jan;48(1):277-83
references.pmid: 19833164
references.citation: Genes Dev. 1998 Jun 1;12(11):1551-70
references.pmid: 9620844
references.citation: Food Chem Toxicol. 2005 Apr;43(4):543-52
references.pmid: 15721201
references.citation: Anticancer Res. 2009 Apr;29(4):1181-7
references.pmid: 19414362
references.citation: Evid Based Complement Alternat Med. 2011;2011:984537
references.pmid: 19131393
references.citation: Oncol Rep. 2004 Mar;11(3):559-95
references.pmid: 14767508
references.citation: Oncogene. 2011 Jul 14;30(28):3139-52
references.pmid: 21317920
references.citation: J Immunol Methods. 1986 May 22;89(2):271-7
references.pmid: 3486233
references.citation: Eur J Cancer B Oral Oncol. 1996 Sep;32B(5):343-6
references.pmid: 8944839
references.citation: J Clin Oncol. 2004 Aug 1;22(15):3061-9
references.pmid: 15284256
references.citation: Clin Cancer Res. 2009 Jul 1;15(13):4312-21
references.pmid: 19509135
references.citation: Mol Cancer Ther. 2005 Sep;4(9):1448-55
references.pmid: 16170038
references.citation: Cancer Biother Radiopharm. 2000 Jun;15(3):295-300
references.pmid: 10941537
references.citation: Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12077-9
references.pmid: 9770441
references.citation: Int J Biol Markers. 2004 Jan-Mar;19(1):58-66
references.pmid: 15077928
references.citation: Nature. 1950 Dec 2;166(4231):949
references.pmid: 14796634
references.citation: J Biol Chem. 1951 Nov;193(1):265-75
references.pmid: 14907713
references.citation: Mol Pharmacol. 2009 May;75(5):1231-9
references.pmid: 19246337
references.citation: Mol Carcinog. 2008 May;47(5):321-5
references.pmid: 17932952
references.citation: Cancer Chemother Pharmacol. 2008 Jul;62(2):305-13
references.pmid: 17912526